0001415889-20-000737.txt : 20200313 0001415889-20-000737.hdr.sgml : 20200313 20200313161015 ACCESSION NUMBER: 0001415889-20-000737 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200310 FILED AS OF DATE: 20200313 DATE AS OF CHANGE: 20200313 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BORKOWSKI EDWARD CENTRAL INDEX KEY: 0001197542 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37853 FILM NUMBER: 20712745 MAIL ADDRESS: STREET 1: 1500 CORPORATE DRIVE STREET 2: SUITE 400 CITY: CANONSBURG STATE: PA ZIP: 15317 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AzurRx BioPharma, Inc. CENTRAL INDEX KEY: 0001604191 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 760 PARKSIDE AVENUE STREET 2: SUITE 304 CITY: BROOKLYN STATE: NY ZIP: 11226 BUSINESS PHONE: 646-699-7855 MAIL ADDRESS: STREET 1: 760 PARKSIDE AVENUE STREET 2: SUITE 304 CITY: BROOKLYN STATE: NY ZIP: 11226 FORMER COMPANY: FORMER CONFORMED NAME: BioPharma d'Azur, Inc. DATE OF NAME CHANGE: 20140331 4 1 form4-03132020_040301.xml X0306 4 2020-03-10 0001604191 AzurRx BioPharma, Inc. AZRX 0001197542 BORKOWSKI EDWARD C/O AZURRX BIOPHARMA, INC. 760 PARKSIDE AVE SUITE 304 BROOKLYN NY 11226 true false false false Common Stock 2020-03-10 4 A 0 14584 0.60 A 393710 D Common Stock 2020-03-10 4 A 0 8414 1.04 A 402124 D Common Stock 2020-03-10 4 A 0 1319 4.74 A 403443 D Common Stock 2020-03-10 4 A 0 6330 4.74 A 409773 D Common Stock 13680 I By Spouse Shares issued in lieu of cash compensation in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending September 30, 2019. Based on the stock price at September 30, 2019, at which time cash compensation would have otherwise been paid for service on the Issuer's Board of Directors. Shares issued in lieu of cash compensation in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending December 31, 2019. Based on the stock price at December 31, 2019, at which time cash compensation would have otherwise been paid for service on the Issuer's Board of Directors. Shares issued in lieu of cash compensation in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending December 31, 2016. Based on the stock price at December 31, 2016, at which time cash compensation would have otherwise been paid for service on the Issuer's Board of Directors. Shares issued in lieu of cash compensation in connection with the Reporting Person's service on the Issuer's Board of Directors during 2016. Based on the stock price at April 21, 2017, at which time cash compensation would have otherwise been paid for service on the Issuer's Board of Directors. /s/ Edward J. Borkowski 2020-03-13